Introduction Postthrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT). PTS develops in 20% to 50% of the patients within the first 2 years after the diagnosis of DVT, 1,2 even when patients are adequately treated with anticoagulants. The sever ity varies from minimal discomfort to severe clini cal manifestations such as chronic pain and intrac table edema. Severe PTS, which includes leg ul ceration, develops in 5% to 10% of the patients.
2-4
The estimated incidence of venous thrombo embolism (VTE) is from 0.7 to 2 per 1000 person years. 5, 6 More than one third of the cases occur in persons older than 60 years of age.
7 VTE is a grow ing public health problem largely due to the aging population. Hence, it is expected that the preva lence of PTS in the population will increase.
The pathophysiology of PTS is not fully under stood, but likely involves the interplay of damage to delicate venous valves in the days to weeks fol lowing acute DVT, residual venous thrombosis or obstruction due to incomplete fibrinolysis, and impaired microcirculation due to persistent ve nous hypertension. [8] [9] [10] This review focuses on the diagnosis and risk determinants of PTS after DVT in adult patients.
to resolve, the optimal timing of diagnosis of PTS is under debate. Over half of the patients meeting the criteria for moderate or severe PTS at 1 month are later reclassified as having milder or no dis ease.
2 Therefore, current recommendations ad vise that a diagnosis of PTS be deferred at least until 3 months after acute DVT.
19
Scoring systems for postthrombotic syndrome There is no goldstandard objective test to diagnose PTS. The condition is primarily diagnosed on clinical grounds in a patient with characteristic manifes tations of PTS and a previous episode of DVT. Six different scales have been used to define PTS in clinical studies: CEAP (clinical, etiologic, anatom ic, pathophysiologic) classification; Widmer clas sification; venous clinical severity score; Villalta scale; Ginsberg definition; and Brandjes scoring than DVT, such as primary venous insufficiency, chronic congestive heart failure, or trauma may produce similar symptoms or signs in the lower extremities. 10 Timing of diagnosis Most cases of PTS develop within 2 years of acute DVT.
1,2,13 However, 2 stud ies demonstrated a gradual increase in the inci dence of PTS during the first 4 to 5 years after DVT, 3, 14 whereas another found no further in crease in the overall incidence of PTS after 1 year, but a gradual increase in PTS severity over time.
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Venous ulcer incidence ranges from 1% to 2% af ter 2 to 5 years 2, 3, 13, 16 and from 2% to 10% up to 10 years after DVT, with a gradual increase in in cidence over time. 17, 18 As the initial pain, leg heaviness, and swelling associated with acute DVT may take 3 to 6 months Duplex sonography of the affected limb has become the initial investigation of choice. It can qualitatively identify the sites of reflux and steno sis. The presence of an echoic lumen, reduced com pressibility, impaired augmentation of flow on dis tal compression, and reduced or absent phasity are qualitative parameters that can help identify previous DVT. 29 Quantitative assessment of the overall severity of reflux when multiple segments are involved can be performed. One of the most important drawbacks of duplex sonography is its inability to properly assess iliac vein thrombus.
Other modalities are used less often owing to limited availability, cost, or invasiveness. In travascular ultrasound can provide better imag es of iliac vein and inferior vena cava thrombi. 30 Ascending venography is an invasive method of obtaining a panoramic view of lower limb venous outflow in the infrainguinal area. Ambulatory ve nous pressure (AVP) provides an overall assess ment of venous dysfunction. 29 AVP is maximal in limbs having venous obstruction with reflux. In vestigations such as magnetic resonance imaging and computed tomography provide 3 dimensional view of the venous tree.
Risk factors for postthrombotic syndrome Because risk factors for PTS are incompletely understood, it is difficult to predict which patients with DVT will develop PTS. Improving our understanding of risk factors is an important initial step toward the development of effective management strat egies for PTS.
Defining risk factors for PTS is an area of on going research: some have been well established, some have been found not to increase the risk for PTS, while others warrant a more rigorous study (TABLE 2) .
Established risk factors for postthrombotic syndrome
Ipsilateral DVT recurrence was found to be the strongest risk factor for the development of PTS (5 to 10 fold increased risk). 1, 3, 31 This find ing underlines the importance of preventing the recurrence of DVT by providing adequate inten sity and duration of anticoagulation following the initial event, as well as of evidence based system. 19, 20 The scales that are most commonly used in clinical practice are the CEAP and Villal ta scales. 21, 22 The CEAP classification was devel oped for chronic venous disease (CVD) in gener al, and combines findings into 7 classes of CVD with subcategories to denote etiologic, anatom ic, and pathophysiologic attributes (TABLE 1). In order to improve standardization of the diagno sis of PTS and allow greater ability to perform cross study comparisons, international guidelines now recommend using the Villalta scale to diag nose PTS and grade its severity 19 (TABLE 1) . The Vil lalta scale shows several advantages over other PTS classifications: specific design for PTS, 1, 20, 22 high interobserver accordance, 15, 20 and accura cy in reflecting patient perceived quality of life and the clinical course of PTS. 12, 13, 15, 20, 23, 24 How ever, the Villalta scale is a clinical measure, and hence does not provide information about the an atomic distribution of the original DVT, wheth er there is residual thrombosis with obstruction or reflux on ultrasonography, and the presence of healed ulcer is not considered. These important ancillary features are reported in the CEAP clas sification that can be used for research purpos es jointly with the Villalta scale for PTS evalua tion.
19,25 A recent systematic review that aimed to assess each of the scoring systems used to di agnose and classify PTS concluded that the Villal ta score, combined with a venous disease specific quality of life questionnaire, should be considered the gold standard for the diagnosis and classifi cation of PTS. 26 
TABLE 2
and femoral veins (>24.5 cm/s), seems to constitute an independent predictor of advanced signs of PTS. However, the proportion of patients with persistent venous occlusion was reported to be the same in patients with CEAP scores of C0-3 and C4-6. Haenen et al. 8 showed reflux in the proximal deep veins to be associat ed with worse CEAP scores, but no such relation was shown for reflux in the superficial veins and distal deep veins and no relation was observed between vein noncompressibility or the combi nation of reflux and noncompressibility and PTS. In a second study, the same group showed super ficial venous reflux to be the most important risk factor for the onset of PTS symptoms, and 64% of patients with severe PTS were shown to have a combination of superficial and deep reflux. 40 In a recently published study of 114 patients fol lowed with ultrasound and air plethysmography, 41 4 risk factors for PTS were identified as best pre dictors: extensive clot load on presentation; clot regression at 6 months not exceeding 50%; ve nous filling index exceeding 2.5 ml/s; and abnor mal outflow rate measured by a 2 second maxi mum outflow volume (<60% of the volume deplet ed after 2 s). Patients with 3 or more of these risk factors had a significant risk of developing PTS with a sensitivity of 100%, specificity of 83%, and positive predictive value of 67%. Patients scoring 2 or less risk factors did not have PTS at 5 years, with a negative predictive value of 100%.
DVT is sometimes diagnosed in asymptom atic patients by performing screening tests in high risk settings, for example, postoperative ly. A meta analysis pooled 7 studies of patients with asymptomatic postoperative DVT and re ported that the overall RR of developing PTS was 1.6 (95% CI, 1.24-2.02) as compared with patients without DVT. 42 These findings indicate that as ymptomatic DVT can lead to PTS, which could help explain the lack of a clinical history of DVT in some patients who have evident postthrom botic limbs. It remains to be determined wheth er the treatment of asymptomatic thrombi im pacts on either the incidence or severity of PTS.
Some data suggests that PTS may be promoted by inadequate initial anticoagulation. Van Don gen et al. 3 showed that patients who spent more than 50% of their time beneath the therapeu tic range during the first 3 months after DVT di agnosis were at an increased risk for developing PTS (odds ratio [OR], 2.71; 95% CI, 1.44-5.10).
3
These results have recently been confirmed in a cohort study of patients with unprovoked DVT, which showed the overall frequency of PTS in patients with subtherapeutic anticoagulation to be 33.5%, compared with 21.6% in those with an international normalized ratio (INR) below 2 for 20% or less of the time (P = 0.01).
43 During the first 3 months of therapy, the adjusted OR thrombophylaxis to prevent DVT in high risk situations.
With regard to the relationship between the lo cation of the initial DVT and the subsequent de velopment of PTS, in most studies, the risk of PTS was higher in patients with proximal rather than distal DVT, 2,16,32,33 whereas in others, the site or extent of thrombosis did not predict the devel opment of PTS. 1, 31, 34 Proximal DVTs are a hetero geneous group, comprising both iliofemoral and femoropopliteal DVT. This distinction is impor tant because, in iliofemoral DVT, the obstruction is often above the entry of the profunda femoral vein, thereby impairing collateral flow and confer ring a greater risk of PTS than popliteal DVTs.
35
A higher body mass index (BMI) is not only a risk factor for VTE, but also increases the risk of PTS by 2 fold and is associated with more se vere PTS. 2, 3, 13, 16, [35] [36] [37] This is an interesting finding because obesity is a modifiable risk factor, and thus, weight reduction might potentially reduce the occurrence or severity of PTS.
The presence of varicose veins prior to the de velopment of DVT is associated with an increased risk of PTS. 13, 35 Therefore, the assessment of pre existing symptoms and signs of CVD at the time of DVT diagnosis might be of interest to identi fy patients at a higher risk of PTS.
Possible risk factors for postthrombotic syndrome
The risk of VTE is known to increase with age, but there does not appear to be a definite association with PTS. Reports in the literature are conflict ing: although some studies have observed an as sociation, 2,17,31,34-36 others have not. 10, 16 Similar ly, some studies have shown men to be at a high er risk for PTS, while others have shown an in creased risk in women. 2, 16, 34, 35 The presence of residual DVT symptoms may also predict an increased risk for PTS. Kahn et al. 2 found that patients with residual DVT symptoms 1 month after the diagnosis of DVT were 4 times more likely to develop PTS than those without re sidual symptoms at 1 month.
2
It is plausible that residual thrombosis as well as physiological changes, including reflux in the affected vein, promote the development of PTS. Johnson et al. 38 showed residual occlusion to be present in 80% of postthrombotic limbs and reflux in 83% (in 65% of the limbs, both oc clusion and reflux were present). Prandoni et al. reported a relative risk (RR) of 1.6 for the devel opment of PTS with the presence of residual vein thrombosis, and 1.7 if both residual vein throm bosis and popliteal vein reflux were present. 9 In a recent study, the RR for PTS was 1.9 (95% con fidence interval [CI], 1.4-2.6) in patients with re sidual vein thrombosis alone; 1.1 (95% CI, 0.7-1. 9) in patients with popliteal vein reflux alone; and 1.8 (95% CI, 1.3-2.7) in those with both residual vein thrombosis and popliteal vein reflux.
34 How ever, other studies found conflicting results. Ya maki et al.
39 studied venous obstruction and mea sured reflux by duplex scanning in a population of VTE. A recent study investigated the role of the SNP 4G/5G of the gene coding for plasmino gen activator inhibitor 1 (PAI 1) in the persistence of thrombotic lesion and the occurrence of PTS. 51 Patients with the 4G/5G polymorphism had in creased PAI 1 activity and increased incidence of persistent thrombosis or the development of PTS or both. A large prospective cohort study by our group, examining the association between various SNPs and PTS is ongoing.
Factors not associated with increased risk of postthrombotic syndrome Reports in the literature have not demonstrated an association between PTS and the type of DVT (unprovoked vs. revers ible risk factors vs. cancer related). 3, 15, 31 This association between inherited and ac quired thrombophilic disorders and PTS has not been substantiated. A recent systematic review and meta analysis of 16 studies did not demon strate a significant association between any of the known thrombophilias and the risk of PTS in patients with DVT. 52 Duration and intensity of long term anticoagu lation does not appear to modulate the risk of de veloping PTS. While secondary prophylaxis with oral anticoagulants for 6 months compared with 6 weeks offered an advantage regarding the rate of VTE recurrence in the DURAC I trial, it did not appear to influence the rate of PTS after a 10 year follow up.
17 These findings were confirmed in a re cent study. 34 In a study involving patients with unprovoked DVT who were treated with oral an ticoagulants for an average of 2 years, there was no difference in PTS occurrence among patients randomized to a lower target INR (1.5-1.9) com pared with conventionalintensity INR (2.0-3.0). 13
Conclusion
After acute DVT, up to half of the pa tients will develop PTS, in most cases, within 1 to 2 years of the acute event. Recurrent ipsi lateral DVT and proximal DVT increase the risk of developing PTS, as does increased BMI. Pre liminary studies suggest that poor quality of ini tial oral anticoagulation could be associated with the development of PTS as well as finding re sidual obstruction and valvular reflux on duplex ultrasonography.
Despite the progress made in recent years, it is still not possible to reliably predict, on an individ ual basis, who will develop PTS after acute DVT. Further studies of clinical determinants and bi ological markers of an increased risk of PTS are needed to ultimately achieve improvements in long term prognosis after DVT.
for developing PTS if a patient had subtherapeu tic anticoagulation was 1.84 (95% CI, 1.13-3.01); the corresponding OR for the full period of anti coagulation was 1. 88 (95% CI, 1.15-3.07 ). There fore, improving the quality of anticoagulant treat ment during the first 3 to 6 months after DVT di agnosis might be of importance to prevent PTS occurrence.
The role of the type of anticoagulant used for the treatment of DVT in relation to PTS is a mat ter of ongoing study. A meta analysis of 9 studies that compared prolonged treatment with LMWH versus oral anticoagulation reported a lower in cidence of venous ulceration in LMWH treated patients. 44 The underlying mechanism could be an anti inflammatory effect of LMWH or the pre vention of the recurrence of subclinical DVT. Along the same lines, the use of new oral anti coagulants (NOACs; direct thrombin or factor Xa inhibitors), by delivering a more predictable quality of therapeutic anticoagulation than that of vitamin K antagonists, could plausibly reduce the occurrence of PTS after DVT, 18,45 but this has not been studied. Clinical and pharmacoeconomic studies are needed to assess the effect of NOACs on the risk of PTS.
Recent research efforts have focused on certain biomarkers as predictors of PTS. Elevated inter leukin 6 and C reactive protein (CRP) are linked to higher venous outflow resistance and incom plete thrombus resolution, 46 and the levels of in tercellular adhesion molecule 1 are higher in pa tients with PTS compared with those without PTS.
47 Median CRP levels, measured 12 months after acute DVT, were increased in patients with PTS compared with those without PTS, and CRP levels exceeding 5 mg/l at 12 months were asso ciated with an OR of 8.0 (95% CI, 2.4-26.4) for PTS development in a prospective cohort study that included 228 patients. 48 Further study is needed to assess the incremental benefit of in flammatory biomarkers as part of a clinical pre diction rule for PTS.
D dimer is a fibrin degradation product that, when elevated, indicates active clot breakdown and can be an indirect marker of coagulation ac tivation.
49 A recent systematic review included 11 studies that investigated the association be tween D dimer levels and PTS. 50 The majority of studies suggested an increased risk of PTS (statis tically significant in 4 of them) with higher D di mer levels; however, no firm conclusion could be reached owing to heterogeneity between stud ies regarding the method and timing of D dimer measurement and the definition of PTS. To fur ther evaluate D dimer as a predictor of PTS, clin ical studies need to standardize the use of either qualitative or quantitative D dimer, as well as the timing and circumstances (e.g., on vs. off an ticoagulants) of D dimer testing.
In recent years, advances have been made in the field of the genetics of VTE by identifying as sociations between genes or variants (single nucle otide polymorphysms [SNPs] ) and the occurrence
